Uptake of hepatitis B-HIV co-infection screening and management in a resource limited setting
Tóm tắt
Từ khóa
Tài liệu tham khảo
Motamedifar MP, et al. The prevalence and risk factors of Hepatitis Delta virus in HIV/HBV co-infected patients in shiraz, Iran, 2012. Iran J Med Sci. 2015;40(5):448–53.
Soriano V, et al. Emerging challenges in managing hepatitis B in HIV patients. Curr HIV/AIDS Rep. 2015;12(3):344–52.
Chen G, et al. Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study. Int J Epidemiol. 2005;34(1):132–7.
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–73.
Baran B, et al. Treatment failure may lead to accelerated fibrosis progression in patients with chronic hepatitis C. J Viral Hepat. 2014;21(2):111–20.
Uto H, et al. Increased rate of death related to presence of viremia among hepatitis C virus antibody–positive subjects in a community-based cohort study. Hepatology. 2009;50(2):393–9.
Kumar R, Singla V, Kacharya S. Impact and management of hepatitis B and hepatitis C virus co-infection in HIV patients. Trop Gastroenterol. 2008;29(3):136–47.
Puoti M, et al. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev. 2002;4(1):27–35.
Matthews GV, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS. 2006;20(6):863–70.
Sulkowski MS, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283(1):74–80.
den Brinker M, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14(18):2895–902.
Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, Yanny I, Razavi H, Vickerman P. Lancet Infect Dis. 2016 Jul;16(7):797–808. doi: https://doi.org/10.1016/S1473-3099(15)00485-5 . Epub 2016 Feb 25. Review.PMID: 26922272.
Chen, D.S., et al., Report from a viral hepatitis policy forum on implementing the WHO framework for global action on viral hepatitis in North Asia: J Hepatol 2013 Nov;59(5):1073–1080. doi: https://doi.org/10.1016/j.jhep.2013.06.029 . Epub 2013 Jul 12.
WHO, Prevention and Control of Viral Hepatitis Infection: Framework for Global Action. 2012: p. 28.
Ocama P, et al. Hepatitis B and HIV co-infection is still treated using lamivudine-only antiretroviral therapy combination in Uganda. Afr Health Sci. 2015;15(2):328–33.
Bwogi J, et al. Hepatitis B infection is highly endemic in Uganda: findings from a national serosurvey. Afr Health Sci. 2009;9(2):98–108.
UNEPI, Uganda National Expanded Program on immunisation. 2002. http://www.nationalplanningcycles.org/sites/default/files/country_docs/Uganda/uganda_epi_cmyp_2012-2016_update_2013.pdf
WHO, Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Vol.. 2013: PMID: http://www.who.int/hiv/pub/guidelines/arv2013/en/
WHO, World Health Organization (WHO) guidelines for the prevention, care and treatment of persons living with chronic hepatitis B (CHB) infection 2015.
MOH guidelines, The 2013 Uganda Ministry of ART Health guidelines 2013 ( http://www.who.int/hiv/amds/uganda_moh_treatment_guidelines.pdf ).
Stockdale AJ, Geretti AM, Chronic h B. Infection in sub-Saharan Africa: a grave challenge and a great hope. Trans R Soc Trop Med Hyg. 2015 Jul;109(7):421–2. https://doi.org/10.1093/trstmh/trv044.
Lemoine M, Eholie S, Lacombe K. Reducing the neglected burden of viral hepatitis in Africa: strategies for a global approach. J Hepatol. 2015;62(2):469–76.
Nwokediuko SC. Chronic hepatitis B: management challenges in resource-poor countries. Hepat Mon. 2011;11(10):786–93.
Lacombe K, et al. HIV/hepatitis B virus co-infection: current challenges and new strategies. J Antimicrob Chemother. 2010;65(1):10–7.
Claire Murphy, E., Challenges of hepatitis B-HIV co-infection screening and management in resource limited settings. BHIVA, Abstract 2012( www.bhiva.org/documents/Conferences/.../HIVMedicine12.pdf ).
Nwaka S, et al. Analysis of pan-African Centres of excellence in health innovation highlights opportunities and challenges for local innovation and financing in the continent. BMC Int Health Hum Rights. 2012;12(11):12–1.
Castelnuovo B, et al. Implementation of provider-based electronic medical records and improvement of the quality of data in a large HIV program in sub-Saharan Africa. PLoS One. 2012;7(12):17.
Wandeler G, et al. Hepatitis B infection, viral load and resistance in HIV-infected patients in Mozambique and Zambia. PLoS One. 2016;11(3)
Teshale EH, et al. Hepatitis B virus infection in northern Uganda: impact of pentavalent hepatitis B vaccination. Vaccine. 2015;29(15):01334–1.
Macro, M.o.H.U.a.O., Uganda HIV/AIDS Sero-behavioural Survey 2004–2005. Calverton, Maryland, USA, 2006: p. 114–116.
Falade-Nwulia O, et al. Incident hepatitis B virus infection in HIV-infected and HIV-uninfected men who have sex with men from pre-HAART to HAART periods: a cohort study. Ann Intern Med. 2015;163(9):673–80.
Marcellin P, et al. Effectiveness and safety of Tenofovir Disoproxil fumarate in chronic hepatitis B: a 3-year, prospective, real-world study in France. Dig Dis Sci. 2016;28:28.
Nikolopoulos GK, et al. HBV-DNA levels predict overall mortality in HIV/HBV coinfected individuals. J Med Virol. 2015;19(10):24357.
Kim JH, Psevdos G Jr, Sharp V. Five-year review of HIV-hepatitis B virus (HBV) co-infected patients in a new York City AIDS center. J Korean Med Sci. 2012;27(7):830–3.
van Meer S, et al. Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands. Eur J Gastroenterol Hepatol. 2015;1:1.